公开(公告)号：US20080305169A1

公开(公告)日：2008-12-11

申请号：US11753247

申请日：2007-05-24

申请人： Kazuki Miki ,  Fuyuki Arimoto ,  Masaki Sunami

发明人： Kazuki Miki ,  Fuyuki Arimoto ,  Masaki Sunami

IPC分类号： A61K9/36 ,  A61K31/538 ,  A61K31/5415 ,  A61K31/55 ,  A61K31/498 ,  A61K31/553 ,  A61K9/28

CPC分类号： C07D209/08 ,  A61K9/2018 ,  A61K9/2077 ,  C07D215/08 ,  C07D223/16 ,  C07D241/42 ,  C07D243/12 ,  C07D265/36 ,  C07D265/38 ,  C07D267/14 ,  C07D279/16 ,  C07D413/06 ,  C07D498/04

摘要： [Problems] The present invention provides pharmaceutical composition which is effective for the prophylaxis or treatment of pathology showing involvement of uric acid (hyperuricemia, gouty tophus, acute gout arthritis, chronic gout arthritis, gouty kidney, urolithiasis, renal function disorder, coronary arterial disease, ischemic heart disease and the like) and the like, and is superior in the time-course stability and dissolution property (disintegration property). [Solving Means] The pharmaceutical composition of the present invention is a pharmaceutical composition comprising a nitrogen-containing fused ring compound represented by the following formula [1] or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable additives, wherein the nitrogen-containing fused ring compound or a pharmaceutically acceptable salt thereof is not in contact with a basic additive: wherein each symbol is as described in the specification.

摘要翻译： [问题]本发明提供了有效预防或治疗尿酸（高尿酸血症，痛风性痛，急性痛风性关节炎，慢性痛风性关节炎，痛风肾，尿路结石，肾功能障碍，冠状动脉疾病 ，缺血性心脏病等）等，并且时间稳定性和溶解性（崩解性）优异。 [解决方案]本发明的药物组合物是包含由下式[1]表示的含氮稠环化合物或其药学上可接受的盐和一种或多种药学上可接受的添加剂的药物组合物， 含有稠环化合物或其药学上可接受的盐不与碱性添加剂接触：其中每个符号如说明书中所述。